Surgery Partners Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Surgery Partners in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Surgery Partners stock.
View analyst ratings for Surgery Partners or view top-rated stocks.

Wall Street analysts have given Surgery Partners a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Surgery Partners wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Surgery Partners saw a decrease in short interest in August. As of August 13th, there was short interest totaling 1,270,000 shares, a decrease of 14.2% from the July 29th total of 1,480,000 shares. Based on an average daily trading volume, of 379,200 shares, the short-interest ratio is presently 3.3 days. Currently, 4.0% of the company's shares are short sold.
View Surgery Partners' Short Interest.

Surgery Partners is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Surgery Partners.

Surgery Partners, Inc. (NASDAQ:SGRY) released its quarterly earnings results on Wednesday, August, 4th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.20) by $0.32. The business had revenue of $543.30 million for the quarter, compared to analyst estimates of $545.08 million. Surgery Partners had a negative net margin of 4.95% and a negative trailing twelve-month return on equity of 1.93%.
View Surgery Partners' earnings history.

Surgery Partners' stock was trading at $8.86 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SGRY shares have increased by 414.2% and is now trading at $45.56.
View which stocks have been most impacted by COVID-19.

Surgery Partners updated its FY 2021 earnings guidance on Wednesday, August, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.20 billion-$2.23 billion, compared to the consensus revenue estimate of $2.23 billion.

4 analysts have issued 1 year target prices for Surgery Partners' shares. Their forecasts range from $35.00 to $61.00. On average, they expect Surgery Partners' share price to reach $48.67 in the next twelve months. This suggests a possible upside of 6.8% from the stock's current price.
View analysts' price targets for Surgery Partners or view top-rated stocks among Wall Street analysts.

7 employees have rated Surgery Partners CEO Eric Evans on Glassdoor.com. Eric Evans has an approval rating of 86% among Surgery Partners' employees.

Some companies that are related to Surgery Partners include Universal Health Services (UHS), Tenet Healthcare (THC), Community Health Systems (CYH), SunLink Health Systems (SSY), Nobilis Health (HLTH), First Physicians Capital Group (FPCG), Ethema Health (GRST), Rennova Health (RNVA) and Rennova Health (RNVAD).
View all of SGRY's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Surgery Partners investors own include Sorrento Therapeutics (SRNE), Rigel Pharmaceuticals (RIGL), Ardelyx (ARDX), Glu Mobile (GLUU), Ocular Therapeutix (OCUL), Sangamo Therapeutics (SGMO), Xilinx (XLNX), Allena Pharmaceuticals (ALNA), Editas Medicine (EDIT) and Maxar Technologies (MAXR).

Surgery Partners trades on the NASDAQ under the ticker symbol "SGRY."

Surgery Partners' stock is owned by many different retail and institutional investors. Top institutional shareholders include Bain Capital Investors LLC (59.49%), FMR LLC (12.13%), Clearbridge Investments LLC (5.91%), Vanguard Group Inc. (5.18%), Price T Rowe Associates Inc. MD (3.26%) and BlackRock Inc. (3.46%). Company insiders that own Surgery Partners stock include Anthony Taparo, George Goodwin, Jennifer Baldock, Laura L Brocklehurst, Teresa Deluca and Thomas F Cowhey.
View institutional ownership trends for Surgery Partners.

SGRY stock was sold by a variety of institutional investors in the last quarter, including Parallax Volatility Advisers L.P., Castleark Management LLC, Goldman Sachs Group Inc., Clearbridge Investments LLC, WCM Investment Management LLC, BNP Paribas Arbitrage SA, Price T Rowe Associates Inc. MD, and Calamos Advisors LLC. Company insiders that have sold Surgery Partners company stock in the last year include Anthony Taparo, George Goodwin, Jennifer Baldock, Laura L Brocklehurst, Teresa Deluca, and Thomas F Cowhey.
View insider buying and selling activity for Surgery Partners or view top insider-selling stocks.

SGRY stock was purchased by a variety of institutional investors in the last quarter, including Bain Capital Investors LLC, Vanguard Group Inc., FMR LLC, Rheos Capital Works Inc., Hood River Capital Management LLC, Dimensional Fund Advisors LP, First Trust Advisors LP, and BlackRock Inc..
View insider buying and selling activity for Surgery Partners or or view top insider-buying stocks.

Shares of SGRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SGRY stock can currently be purchased for approximately $45.56.

Surgery Partners has a market capitalization of $3.76 billion and generates $1.86 billion in revenue each year. The company earns $-116,100,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis.

Surgery Partners employs 10,800 workers across the globe.

The official website for Surgery Partners is www.surgerypartners.com.

Surgery Partners is headquartered at 310 Seven Springs Way Suite 500, Brentwood TN, 37027.

Surgery Partners' mailing address is 310 Seven Springs Way Suite 500, Brentwood TN, 37027. The company can be reached via phone at (615) 234-5900 or via email at [email protected].